Feb 28 (Reuters) - EMA's CHMP:
EMA'S CHMP: VYJUVEK (BEREMAGENE GEPERPAVEC) RECEIVE POSITIVE OPINION TO TREAT WOUNDS IN PATIENTS OF ALL AGES WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA
EMA SAYS CHMP: CONCLUDED THAT ITS OPINION RECOMMENDING MARKETING AUTHORISATION FOR LEQEMBI (LECANEMAB) DOES NOT NEED TO BE UPDATED
EMA'S CHMP: EXTENSION TO EXISTING INDICATION OF CHIKUNGUNYA VACCINE IXCHIQ TO INCLUDE ACTIVE IMMUNISATION OF ADOLESCENTS FROM 12 YEARS OF AGE
EMA'S CHMP: FABHALTA GETS POSITIVE OPINION FOR EXTENSION OF INDICATION FOR TREATMENT OF ADULT PATIENTS WITH COMPLEMENT 3 GLOMERULOPATHY
EMA'S CHMP: RECOMMENDS APPROVAL OF DEQSIGA FOR PRIMARY, SECONDARY IMMUNODEFICIENCIES AND AUTOIMMUNE DISEASE IMMUNOMODULATION
Source text: [ID:]
Further company coverage: KRYS.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.